Cytochrome P-450 CYP2B6 (CYP2B6)

A cytochrome P450 enzyme subtype that oxidizes a diverse array of XENOBIOTICS. The expression of CYP2B6 varies widely between individuals which is due to the high rate of GENETIC POLYMORPHISMS. Examples of drugs metabolized by CYP2B6 include BUPROPION; efavirenz; CYCLOPHOSPHAMIDE; and MEPERIDINE.

Also Known As:

Networked: 281 relevant articles (11 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Haas, David W: 6 articles (10/2021 - 07/2006)
2.	Sukasem, Chonlaphat: 5 articles (01/2022 - 12/2012)
3.	Zanger, Ulrich M: 5 articles (12/2020 - 07/2006)
4.	Khoo, Saye: 5 articles (01/2020 - 06/2011)
5.	Dandara, Collet: 5 articles (09/2015 - 08/2013)
6.	Masimirembwa, Collen: 4 articles (01/2021 - 04/2008)
7.	Manosuthi, Weerawat: 4 articles (01/2020 - 01/2013)
8.	Morse, Gene D: 4 articles (01/2020 - 09/2010)
9.	Beaune, Philippe: 4 articles (01/2019 - 05/2005)
10.	de Waziers, Isabelle: 4 articles (01/2019 - 05/2005)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 01/15/2014 - "CYP2B6*6 is associated with increased breast cancer risk." 01/15/2014 - "To assess potential associations between two functional polymorphisms CYP2B6_516_G>T (rs3745274) and CYP2B6_785_A>G (rs2279343) and breast cancer risk, we established a specific matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay. " 03/16/2010 - "Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer." 07/01/2008 - "The homozygote of CYP2B6*6 patients with malignant lymphoma and breast cancer treated with CPA showed higher clearance and shorter half-life of plasma CPA. " 01/01/2021 - "The aim of this study was to assess the relationship between CP bioactivation with CYP2B6 and CYP2C19 genotype, as well as CYP2C19 phenotype, in breast cancer patients. "
2.	HIV Infections (HIV Infection) 12/20/2016 - "The presence of 3-OH NVP can probably be used to distinguished CYP2B6 activity and efficacy of nevirapine in patients with HIV infection." 01/01/2015 - "The main aim of this study was to investigate the effect of CYP2B6 gene polymorphisms on efavirenz (EFV) plasma concentrations in Han Chinese patients with human immunodeficiency virus (HIV) infection. " 01/01/2017 - "CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection." 01/01/2015 - "Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection." 12/01/2010 - "Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection."
3.	Opioid-Related Disorders (Opiate Addiction) 07/01/2013 - "CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction." 01/01/2014 - "Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis." 08/01/2016 - "Our study indicates that the CYP2B6*6 allele is associated with a lower pain threshold and lower pain tolerance among males with opioid dependence on MMT. " 01/01/2017 - "In pharmacogenetics of opioid addictions, methadone dose may be regulated by variants in cytochrome P450 2B6 (CYP2B6), a methadone-metabolizing enzyme, and by a locus 300 kb 5' to OPRM1. " 01/01/2018 - "Variants in six pharmacokinetic genes (CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4) and five pharmacodynamic genes (HTR2A, OPRM1, ADRA2A, COMT, SLC6A4) were genotyped in samples from a 24-week, randomized, open-label trial of methadone and buprenorphine/naloxone for the treatment of opioid dependence (n = 764; 68.7% male). "
4.	Hypoxia (Hypoxemia) 01/01/2019 - "Our results indicate that by stimulating HIF‑1α activity, hypoxia downregulates the expression of CYP2B6, CYP3A4 and CYP3A5, that in turn leads to decreased conversion of CPA and IFA into their active forms and thus to diminished cytotoxicity. " 02/01/2000 - "We have used a hypoxia-regulated adenoviral vector to transduce human macrophages with either a reporter or a therapeutic gene encoding human cytochrome P4502B6 (CYP2B6). " 02/01/2011 - "Macrophages were transduced with an adenoviral vector that expresses human cytochrome CYP2B6 via a synthetic hypoxia responsive promoter (OBHRE) and with human P450 reductase (P450R), via the CMV promoter. " 01/01/2019 - "Hypoxia decreased CPA and IFA cytotoxicity in medulloblastoma cells, which correlated with a reduction in the protein levels of CYP2B6, CYP3A4 and CYP3A5 and inhibition of cell proliferation. " 01/01/2019 - "Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia‑inducible factor 1α‑mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation."
5.	Chronic Kidney Failure (Chronic Renal Failure) 07/01/2008 - "In addition, homozygous CYP2B6*5 patients with proliferative lupus nephritis had a significantly higher probability of reaching end-stage renal disease by pulse CPA treatment. " 05/01/2011 - "Patients with SLE (n = 237), unclassified autoimmune disease (n = 51), and healthy controls (n = 294) were genotyped for CYP2B6*5 and CYP2C19*2. Associations between these alleles and achievement of complete or partial response, development of end-stage renal disease, and time to remission were determined. " 07/01/2004 - "In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051). " 03/01/2014 - "In this study, the direct inhibitory effect of serum from chronic renal failure (CRF) patients receiving dialysis was evaluated in CYP3A4 (testosterone) and CYP2B6 (bupropion) metabolism assays. "

Related Drugs and Biologics

1.	Cytochrome P-450 CYP2C19
2.	Cytochrome P-450 CYP2C9
3.	Cytochrome P-450 CYP3A
4.	Cytochrome P-450 CYP2D6 (CYP2D6)
5.	Cytochrome P-450 CYP1A2 (CYP1A2)
6.	Enzymes
7.	Cyclophosphamide (Cytoxan)
8.	Cytochrome P-450 CYP2E1 (CYP2E1)
9.	Cytochrome P-450 CYP1A1 (CYP1A1)
10.	Methadone (Dolophine)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Combination Drug Therapy (Combination Chemotherapy)
4.	Precision Medicine
5.	Subcutaneous Infusions